CME: Advances in Severe Asthma: Highlights from CHEST 2019

Advances in Severe Asthma: Highlights from CHEST 2019

Advances in Severe Asthma: Highlights from CHEST 2019

Keeping pace with data from major conferences is overwhelming. But luckily, this expert discussion reviews emerging data presented at CHEST 2019.

Available credits: 0.25

Time to complete: 15 Minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Recent advances in our understanding of the pathophysiology of asthma have led to improved control, particularly for those patients with moderate-to-severe disease who remain uncontrolled after receiving traditional asthma therapies. Keeping pace with these guidelines and emerging data from major conferences can quickly become overwhelming, so to help healthcare professionals stay up to date, this expert discussion reviews key data presented at CHEST 2019.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Nicola A. Hanania, MD, MS
    Associate Professor
    Baylor College of Medicine
    Houston, TX

    Consulting Fees: AstraZeneca, Genentech, Genzyme, GlaxoSmithKline, Novartis, Regeneron, Sanofi              Contracted Research: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Sanofi Genzyme

    Reynold A. Panettieri, Jr., MD
    Professor of Medicine
    Robert Wood Johnson Medical School
    Vice Chancellor, Clinical & Translational Science
    Director, Rutgers Institute for Translational Medicine and Science
    Rutgers University
    New Brunswick, NJ
    Emeritus Professor of Medicine, University of Pennsylvania
    Philadelphia, PA 

    Consulting Fees: AstraZeneca, Avillion, Boehringer-Ingelheim, Equillium, Medimmune, RIFM, Sanofi/Regeneron, Theravance
    Contracted Research:  AstraZeneca, Equillium, Genentech, Medimmune, RIFM, OncoArendi, Teva, Theratrophix
    Other: AstraZeneca, Genentech, Sanofi/Regeneron

    Reviewers/Content Planners/Authors:

    • Jennifer Caudle, DO has nothing to disclose.
    • Stephen Chavez has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry A. Feidel, PhD has nothing to disclose.
    • William A. Mencia, MD has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify poorly controlled asthma patients to intensify treatment where appropriate
    • Demonstrate an improved understanding of current and emergent science of asthma control
  • Target Audience

    This activity is designed to meet the educational needs of pulmonologists, allergists, pediatricians, primary care physicians, nurse practitioners, physician assistants and other members of the care team who see and treat patients with asthma.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative (GLC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    GLC designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free